Validity of the Montreal Cognitive Assessment in the Detection of Cognitive Dysfunction in Huntington's Disease
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10189449" target="_blank" >RIV/00216208:11110/13:10189449 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00064165:_____/13:10189449
Výsledek na webu
<a href="http://dx.doi.org/10.1080/09084282.2012.670158" target="_blank" >http://dx.doi.org/10.1080/09084282.2012.670158</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/09084282.2012.670158" target="_blank" >10.1080/09084282.2012.670158</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Validity of the Montreal Cognitive Assessment in the Detection of Cognitive Dysfunction in Huntington's Disease
Popis výsledku v původním jazyce
The purpose of this study was to assess the convergent and discriminative validity of the Montreal Cognitive Assessment (MoCA) as a screening tool for cognitive dysfunction in Huntington's disease (HD). Twenty HD patients with cognitive deficit and 23 normal controls (NC) without cognitive deficit were matched for age, sex, and education. The mean MoCA score was 20.5 (SD=5.5) in HD and 27.5 (SD=2.2) in NC. The MoCA correlated in both samples with the brief cognitive battery composite score (r=.81, p<.001). With the screening and diagnostic cutoff scores determined at <26 points, the MoCA showed a sensitivity of 94% and a specificity of 84% in the detection of cognitive dysfunction in HD. The area under the receiver-operating characteristics curve (95%confidence interval) for the MoCA was 0.90 (0.8090.997), p<.001. Our results show that the MoCA is a suitable tool for assessing cognitive dysfunction in patients with HD.
Název v anglickém jazyce
Validity of the Montreal Cognitive Assessment in the Detection of Cognitive Dysfunction in Huntington's Disease
Popis výsledku anglicky
The purpose of this study was to assess the convergent and discriminative validity of the Montreal Cognitive Assessment (MoCA) as a screening tool for cognitive dysfunction in Huntington's disease (HD). Twenty HD patients with cognitive deficit and 23 normal controls (NC) without cognitive deficit were matched for age, sex, and education. The mean MoCA score was 20.5 (SD=5.5) in HD and 27.5 (SD=2.2) in NC. The MoCA correlated in both samples with the brief cognitive battery composite score (r=.81, p<.001). With the screening and diagnostic cutoff scores determined at <26 points, the MoCA showed a sensitivity of 94% and a specificity of 84% in the detection of cognitive dysfunction in HD. The area under the receiver-operating characteristics curve (95%confidence interval) for the MoCA was 0.90 (0.8090.997), p<.001. Our results show that the MoCA is a suitable tool for assessing cognitive dysfunction in patients with HD.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FH - Neurologie, neurochirurgie, neurovědy
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
Z - Vyzkumny zamer (s odkazem do CEZ)
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Applied Neuropsychology
ISSN
0908-4282
e-ISSN
—
Svazek periodika
20
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
8
Strana od-do
33-40
Kód UT WoS článku
000316380000005
EID výsledku v databázi Scopus
—